Thomas Barbato: Yeah, I mean, I think we should expect some continued investments, we’ve talked about some of the heavy lifting being behind us. But I think we’re — you know, we should expect some moderate increases going forward. We continue to invest in sales, we continue to make some investments in IT and cyber security, which you just need to do. But we believe a lot of the heavy lifting is behind us with the increases that we saw in last year, the year before.
Ted Jackson: Okay. And then one last question and then I’ll get out of line. On the customer base lab front, can you talk a little bit about kind of pipeline and activity on that front?
Lee Rudow: Yeah, I’ll take that one, Ted, this is Lee. Yeah, the CBL pipeline is pretty solid. In fact, that I would say it’s very solid, as solid as it’s ever been. We expect that to continue. I mean as long as the labor market is tight, and you know, I’m not going to suggest we’re the only company that services CBLs, but it’s certainly where we have an expertise level in that, that is different than our competition. I think we’re really well-positioned to do well in that space. So I would expect throughout the remainder of this year and into next, that the pipeline we have will support strong growth there.
Ted Jackson: Okay. I’ll get out of line. Again congrats on the quarter. Thanks for taking my questions.
Lee Rudow: Thank you, Ted.
Thomas Barbato: Thank you, Ted.
Operator: [Operator Instructions] Our next question is from Martin Yang with Oppenheimer & Company. Please proceed.
Martin Yang: Good morning. Thank you for taking the question, Lee and Tom. Can you maybe talk about NEXA, give a sense of how the business has grown by itself and what are the synergies, especially revenue synergies you have seen between NEXA and your calibration in distribution business thus far? And finally maybe outlook for the NEXA combined with SteriQual, how that overall consulting business can grow in the longer term? Thanks.
Lee Rudow: Okay, so we acquired NEXA seems like about 2.5 years ago, roughly. So, the business has done really well. We acquired at the time business that since doubled in size, more than doubled in size in that period of time. And we think it’s performing — we think it’s performing very well. There’s a lot of synergies, Martin, that we’ve been able to leverage, take advantage of between Transcat and NEXA mostly, but there’s two avenues of synergies that we’ve performed well. And one is, we’ve given NEXA access to our customer base, and some of that growth, since they more than doubled comes from Transcat traditional customers who are interested in NEXA services. And that’s been very clear and evident — that’s been a clear and evident synergy for us.
The second one has been when Transcat goes to the table and is trying to win a new opportunity, whether it be a CBL or a traditional onsite or a traditional body of work, we have NEXA sitting at the table with us often. And so, not only are we talking about winning an opportunity that we currently don’t have, that our competition has or an in-house lab is running, and with NEXA sitting by our side, we’re able to strengthen our value proposition. Our chances of winning increase significantly. We’ve won deals that we would have otherwise not won on the traditional Transcat side, because NEXA partnered with us in our proposal. So I think it goes both ways, the synergies and we’ve done a really nice job. And I see that continuing and maybe improving as we go forward and get to you know how to work with — work with each other better, get to know each other’s companies.
